~~<i id='C70895D679'><strike id='C70895D679'><tt id='C70895D679'><pre id='C70895D679'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

entertainment

author：hotspot 2025-09-03 18:40:40 - browse：1981

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Menendez indictment could see pharma lose a key ally

explore

focus

explore

leisure time

hotspot

NationalInstitutesofHealthDirectorMonicaBertagnollitestifiesduringherSenateHELPCommitteeconfirmation

WSS

Ohio still needs to do more to protect the right to abortion

Medical school prerequisites are outdated

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Why do women spend more than men on medical expenses?

Ionis has late

hotspot

entertainment

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Data show record exodus of life scientists from academia

Continuity nursing helped my family in our darkest PICU moments

Experimental asthma app from Apple and Anthem shows promise

Medical leaders decry Supreme Court decision on affirmative action

Menendez indictment could see pharma lose a key ally

How to save PrEP access — and even expand it

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Apple is now the first public company to be valued at $3 trillion

CVS, Rite Aid closures threaten to worsen pharmacy deserts

focus

Kaiser Permanente unions announce official strike date

How the Dana

FDA advisers vote against ALS treatment from BrainStorm

Type 2 diabetes prevention programs work at large scale: study

Did you have Obamacare on your GOP debate bingo card?

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

explore

leisure time

hotspot

hotspot